Bankrupt DNA testing company 23andMe to be bought by Regeneron
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million USD through a bankruptcy auction, the companies said on Monday.
Regeneron said it will comply with 23andMe's privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer.
The bankruptcy proceedings, filed in March, had drawn scrutiny from lawmakers who warned that millions of customers' genetic data could be sold to unscrupulous buyers.
23andMe last month agreed to allow a court-appointed overseer for the company's handling of customers' genetic information and its security policies during the bankruptcy.
The company has collected genetic data from 15 million customers who ordered its DNA testing kits online and provided saliva samples.
The company had been struggling with weak demand for its ancestry testing kits and a data breach in 2023 that exposed millions of customers' genetic data.
As part of the agreement, Regeneron will acquire all units of 23andMe, except telehealth service Lemonaid Health, which the genetic testing firm plans to wind down.
After the transaction completes, 23andMe will continue to operate as a wholly owned direct or indirect unit of Regeneron, the companies said.
The companies expect to close the deal in the third quarter of this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
32 minutes ago
- CTV News
Will visa delays and border fears keep international fans away from the Club World Cup in the U.S.?
Fans fill the Rose Bowl as Chelsea plays Liverpool FC in an International Champions Cup soccer match , July 27, 2016, in Pasadena, Calif. (Carlos Delgado/AP Images for International Champions Cup, via AP, File) As the United States readies for the FIFA Club World Cup, concern over such things as international travel, fan safety and even economic uncertainty threaten to diminish enthusiasm for the tournament. The United States will see the arrival of 32 professional club teams from around the globe to 11 cities for the tournament. There's a US$1 billion prize pool. The Club World Cup is considered in many ways to be a dress rehearsal for the big event, the 2026 World Cup to be hosted by the United States, Canada and Mexico. But there seems to be little buzz for the Club World Cup at home or abroad. The expansion of the field from seven to 32 teams has diminished the exclusivity of the event, and ticket sales appear slow. At the same time, the tournament is being played amid reports of foreign tourists being detained and visa processing delays. Chaotic U.S. Immigration and Customs Enforcement activities and U.S. President Donald Trump's travel bans aren't exactly reassuring international fans, either. Wary travelers, visa woes Trump's policies appear to have already impacted travelers. The U.S. National Travel and Tourism Office released data showing visitors to the U.S. from foreign countries fell 9.7 per cent in March compared to the same month last year. The travel forecasting company Tourism Economics has predicted that international arrivals would decline 9.4 per cent this year. The U.S. Travel Association, a nonprofit group that represents the travel industry, has urged the Trump administration to improve such things as visa processing and customs wait times ahead of a series of big sporting events on U.S. soil, including the Club World Cup beginning June 14, the Ryder Cup later this year, next summer's World Cup, and the 2028 Los Angeles Olympics. Association President Geoff Freeman said, for example, that the wait in Colombia for a visa interview appointment is upwards of 18 months — already putting the 2026 World Cup out of reach for some travelers. He said his organization is working with the White House's World Cup Task Force to address issues. 'They (the task force) recognize how important this event is: success is the only option. So we're eager to work with them to do whatever it is we need to do to ensure that we can welcome the millions of incremental visitors that we think are possible,' Freeman said. 'But these underlying issues of visa and customs, we've got to address.' Secretary of State Marco Rubio, speaking at a House Committee on Foreign Affairs hearing last month, suggested consular staff could be put on longer shifts and that artificial intelligence could be used to process visas. 'We want it to be a success. It's a priority for the president,' said Rubio. But the Trump administration may have added to the concerns for international visitors by issuing a ban on travelers from 12 countries, with restrictions on travel from nine more countries. Iran, one of the countries named, has qualified for the World Cup. The proclamation included an exemption for 'any athlete or member of an athletic team, including coaches, persons performing a necessary support role, and immediate relatives, traveling for the World Cup, Olympics, or other major sporting event as determined by the secretary of state.' It did not mention fans. Fan fears There are signs current immigration policies were already impacting soccer fans and spurring worries over safety. A Latin American supporters group in Nashville stayed away from a recent Major League Soccer game because of ICE activity in the city. The city's Geodis Park is set to host three Club World Cup matches. Danny Navarro, who offers travel advice to followers on his social media platforms under the moniker TravelFutbolFan, said the World Cup Task Force announcement did not allay fears about travel, especially when Vice President JD Vance said, 'We want them to come. We want them to celebrate. We want them to watch the game. But when the time is up, they'll have to go home. Otherwise, they'll have to talk to (U.S. Homeland Security) Secretary (Kristi) Noem.' That insinuated fans visiting the United States for the World Cup could use it to stay in the country, which is nonsensical, Navarro maintained. For many countries, fans traveling to the World Cup — an expensive travel plan with hiked flight and hotel prices — are broadly viewed as higher-spending and lower-risk for host nation security planning. Navarro put the onus on FIFA. 'They must know that there is an anxiety among international travelers wanting to come in. They must know there's an anxiety among the U.S. fan base that is multicultural and wanting to go to all these places. Are they going to? Are they going to be harassed by ICE?' Navarro said. 'There is just a lot of uncertainty, I would say, too much uncertainty, that the fan base doesn't want to think about.' If you build it, will they come? It remains to be seen how outside factors will ultimately impact the Club World Cup, which is not the global spectacle or draw that the World Cup is. Ticket sales, which were based on a dynamic pricing model, appear to be slow, with lowered prices from earlier this year and a slew of recent promotions. For a match between Paris Saint-Germain and Botafogo at the Rose Bowl on June 19, there were wide swaths of available seats going for $33.45. FIFA created an incentive program that says fans who buy two or more tickets to the Club World Cup 'may' be guaranteed the right to purchase one ticket to the World Cup next summer. Navarro said economic uncertainty and fears of inflation may make fans hesitant to spend their money on the Club World Cup — when the more desirable World Cup is looming. In some host cities, there's little sign the Club World Cup is happening. A light rail station in Seattle had a lone sign advertising the event. The Seattle Sounders are among the teams playing in the tournament. Hans Hobson, executive director of the Tennessee State Soccer Association, suggested part of the problem is that, unlike the national teams that play in the World Cup, some of the club teams playing in Nashville are just not known to U.S. fans. 'It's not leagues that they watch. If it was the Premier League or the Bundesliga or something like that, then they'd go, 'Oh, I know players there. Let's go check it out,' Hobson said. There were tickets available to LAFC's match against Esperance Sportive de Tunisie in Nashville on June 20 for $24.45. FIFA President Gianni Infantino has traveled to several host cities to gin up enthusiasm. He has promised 'the world will be welcomed.' But some say the United States isn't exactly rolling out the red carpet for visitors in the current climate. 'I could see trepidation for anyone looking to travel to the U.S. at this current political climate,' said Canadian national team coach Jesse Marsch. 'So it's a sad thing, I think, that we have to talk about visiting the U.S. in this way but I think everybody has to make decisions that are best for them and that fit best with what's going on in their life and their lifestyle.' AP Sports Writer Teresa Walker contributed to this report Anne M. Peterson, The Associated Press
Globe and Mail
41 minutes ago
- Globe and Mail
Is Palantir Still a Buy After Its Run-Up? 3 Analysts From The Motley Fool Weigh In.
One of the fastest-growing stocks in artificial intelligence (AI) over the last year is Palantir Technologies (NASDAQ: PLTR). Its Artificial Intelligence Platform (AIP) brought eye-popping productivity gains to its customers. Investors took notice, as the stock is up by 420% over the last year. Unfortunately for investors who have recently taken an interest, its forward P/E ratio is 205, and it sells for 96 times sales. Knowing that, three analysts from The Motley Fool have weighed in to determine whether its stock is still worth buying at these levels. Is Palantir a repeat lesson from the dot-com era? Justin Pope: Separating noise from signal is arguably the most challenging aspect of investing. For Palantir, the noise is a red-hot stock price. Shares of Palantir have risen a mind-melting 1,770% since 2023. In other words, buying the stock up to this point has looked like a genius move. Anyone seeing this, especially on social media, where people aren't always humble, might feel tempted to jump into the stock. But here is the signal. The stock is rising faster than Palantir's underlying business has grown. Don't get me wrong, I think Palantir is an excellent AI stock, and the company is executing at a high level, particularly since launching AIP two years ago. It can make a stock appear invincible when prices only go up. However, investors have seen this movie before. Cisco Systems ran to wildly excessive valuations during the infamous dot-com bubble in the late 1990s. It lost most of its value when the bubble burst, and still hasn't revisited its all-time high, a whopping 25 years later. That doesn't mean that Palantir will suffer the same fate, but check this out. Cisco's P/E ratio peaked at approximately 234, and its price-to-sales (P/S) ratio peaked at around 39. Palantir is even more expensive today than Cisco at its peak. CSCO data by YCharts At the very least, it's hard to imagine much more rational upside in Palantir from these levels. Even worse, any market downturn or misfire in Palantir's business could pop that valuation bubble. Investors should tread very carefully around Palantir stock these days. Amazon's stock history holds a valuable lesson for those worried about Palantir's lofty valuation Jake Lerch: Here's a sentiment that I often hear: "I love the stock, but it's too late to buy it now." And while there's nothing wrong with this viewpoint in theory, I've seen it disproven too many times in practice to grant it much weight. Take Amazon, for example. For years, countless analysts pointed out -- for good reason -- that Amazon's valuation was sky-high. From 1997 through 2000, Amazon's average P/S ratio was around 16. Moreover, the company had no profits -- and therefore no P/E ratio -- until 2003. Once it was making money, Amazon's average P/E ratio over its first five years of profitability was an eye-popping 88. Yet, investors who bought Amazon -- and held until today -- would be very happy with the results. In fact, $10,000 invested in the stock in 2008 would be worth about $800,000 today. This is all to point out that valuation isn't everything. Yes, Palantir is an expensive stock by just about any measure. Its current P/S and P/E ratios are significantly higher than the historical averages I cited for Amazon. However, that's because Palantir is poised to deliver enormous growth over the next decade or more. The company offers a unique value proposition that appeals to almost every organization. It can deliver efficiency gains for government agencies;it can cut costs for commercial clients. It can even help military and intelligence agencies win wars and prevent terrorist attacks. Simply put, there's very little this company can't do. Lastly, the nature of AI and data analysis means that Palantir is positioned to benefit from significant network effects and economies of scale as its AI systems improve and the company's overall client list grows. On top of that, its revenue is already growing at a year-over-year rate of 39%, andprofits are increasing, as is free cash flow. That's what gives me confidence to believe it's not too late to buy Palantir stock. Palantir is a winner for customers, but not investors Will Healy: When it comes to AI living up to its potential, perhaps no stock outshines Palantir. The company began in 2003 and utilizes AI and machine learning as a national security-focused tool. However, it was only when Palantir began to benefit from AIP's massive productivity gains that its popularity took off. Anduril Industries had a 200-fold efficiency gain in its ability to respond to supply shortages. A global insurer reduced an underwriting workflow from two weeks to three hours. With results like that, it is little wonder its commercial customer count is up fivefold over the past three years. Such gains undoubtedly played a role in the aforementioned stock price growth, but regrettably for Palantir bulls, the increases likely do not justify the software-as-a-service (SaaS) stock 's valuation, and here's why. In Q1, revenue of $884 million rose 39% compared to year-ago levels. With that growth, its net income of $214 million surged 103% higher over the same period. Unfortunately, triple-digit growth is not sustainable for even the best of companies, and the current valuation likely prices it for perfection. That "perfection" is likely not in the cards for Palantir. Analysts forecast revenue growth will slow to 36% for 2025 before falling to 29% in 2026. That is likely to do little to make the 96 P/S ratio more attractive, particularly when the larger and faster-growing Nvidia sells for 24 times sales. Indeed, Palantir is likely to play a key role in the AI field for years to come. Nonetheless, valuation matters at some point, and investors could find themselves stuck in a losing stock for years to come if the sentiment around the stock starts to turn negative. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Jake Lerch has positions in Amazon and Nvidia. Justin Pope has no position in any of the stocks mentioned. Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Cisco Systems, Nvidia, and Palantir Technologies. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
How would you like to get paid every quarter (and sometimes every month) to own a stock? That's exactly what happens when you invest in dividend stocks. Sometimes, the amount you are paid to own these stocks can be very attractive. Three Motley Fool contributors believe they've found stocks you can buy right now that have mouthwatering dividends. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). A top dividend stock for the long haul Prosper Junior Bakiny (AbbVie): Several factors make for an above-average dividend stock. AbbVie, a pharmaceutical company, checks many of those boxes. Consider the company's forward yield, which currently tops 3.5% versus the 1.3% average for the S&P 500. Although a stock can be attractive for dividends with a relatively low yield, income seekers often like juicy ones, and AbbVie's is. We can also point to AbbVie's fantastic track record. The company is a Dividend King with an active streak of 53 consecutive payout increases. That suggests AbbVie is unlikely to slash its payouts anytime soon, as doing so would force the company to start the streak from scratch and maybe rejoin this exclusive club in another 50 years. Of course, AbbVie might be forced to cut its dividends if the business faces significant headwinds. However, that's yet another area where the company excels, which makes it a top dividend stock. AbbVie is a leading drugmaker with a deep lineup of products that generate consistent revenue and earnings. Some of the company's medicines continue increasing their sales at a good clip. AbbVie's two biggest growth drivers are Skyrizi and Rinvoq, a pair of immunology medicines. These therapies have surprised even the company's management, which recently increased Skyrizi and Rinvoq's combined 2027 guidance by $4 billion to more than $31 billion. AbbVie's lineup features several other key products, including its Botox franchise. And although it will face patent cliffs, as every drugmaker does, AbbVie also has a deep pipeline of investigational compounds that will eventually allow it to move beyond its current crop of therapies. All these things (and more) make AbbVie an attractive dividend stock. Income investors can safely add shares of the company to their portfolios and hold on to them for a long time. Bristol Myers stock pays 5% and has underrated growth potential David Jagielski (Bristol Myers Squibb): A dividend stock that income investors might want to consider loading up on right now is that of pharma giant Bristol Myers Squibb. It currently yields 5.1%, which is a higher-than-typical payout for this top healthcare company. At such a high yield, you may be concerned that it's unsustainable, but that's not the case. The company's fundamentals are sound. In the trailing 12 months, Bristol Myers generated free cash flow totaling $13.1 billion, which is more than double the amount it has paid out in cash dividends during that stretch ($4.9 billion). In each of the past four years, Bristol Myers' free cash flow has totaled at least $11 billion. The company has been struggling with growth in recent years due to rising competition and the loss of patent protection on key drugs. But its growth portfolio has been giving investors a reason to remain optimistic. Through the first three months of the year, its non-legacy products generated year-over-year growth of 18% when excluding foreign exchange. Bristol Myers has been a solid name in healthcare for years, and while it's facing adversity, it's still growing. Last year, it obtained approval for schizophrenia drug Cobenfy, which may generate peak sales of up to $10 billion, according to some analysts. At 18 times trailing earnings, this can be a great, cheap dividend stock to add to your portfolio today. A safer dividend than initially meets the eye Keith Speights (Pfizer): Investors are right to be at least somewhat skeptical when they see a stock with a super-high dividend yield. For example, Pfizer's forward dividend yield is 7.38%. Is a dividend cut on the way for the big pharmaceutical company? I don't think so. Granted, Pfizer's dividend payout ratio of 122.5% might seem worrisome. However, the company generates enough free cash flow to cover its dividend at the current level. The amount of free cash flow could also increase as a result of Pfizer's cost-cutting initiatives. The drugmaker's dividend is safer than initially meets the eye, in my view. I believe Pfizer's underlying business is also stronger than it might look at first glance. It's easy to focus only on the negatives. There are several, including a steep decline in COVID-19 product sales, some notable pipeline setbacks, the upcoming loss of exclusivity for multiple top-selling drugs, and the Trump administration's threats of tariffs on pharmaceutical imports. But Pfizer has plenty of positives that offset those negatives. For one thing, I think its valuation more than reflects all the challenges, with shares trading at only 8 times forward earnings. The company also has several new products with fast-growing sales and a robust pipeline. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
